Pfizer (PFE) Chairman and CEO Albert Bourla discusses the $43 billion acquisition of cancer biotech company Seagen Inc. (SGEN), for which U.S. approval is still pending. The integration of Seagen will require additional investment, but is expected to generate $10 billion in revenues by 2030. Finally, despite the recent wave of consolidation in the sector, he anticipates few major mergers and acquisitions in 2024.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.